Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity.
暂无分享,去创建一个
S. Neuhausen | E. Friedman | L. K. Boker | L. Ottini | Y. Laitman | L. Steele | H. Shani | B. Silverman | T. Perri | J. Korach | Valentina Silvestri | E. Friedman
[1] G. Iwasiuk,et al. Persistent Mullerian Duct Syndrome Presenting in an Incarcerated Recurrent Inguinal Hernia with Hydrocele , 2017, Urology case reports.
[2] V. Tuohy,et al. Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II , 2015, Journal of immunology research.
[3] P. Radice,et al. Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy. , 2015, European journal of cancer.
[4] E. Friedman,et al. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers , 2015, Breast Cancer Research and Treatment.
[5] C. Bascoul-Mollevi,et al. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer , 2014, mAbs.
[6] S. Ogura,et al. Photodynamic detection and management of intraperitoneal spreading of primary peritoneal papillary serous carcinoma in a man: report of a case , 2014, Surgery Today.
[7] I. Shih,et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesions , 2012, The Journal of pathology.
[8] S. Neuhausen,et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States , 2011, Breast Cancer Research and Treatment.
[9] Yurii B. Shvetsov,et al. Incidence of Ovarian, Peritoneal, and Fallopian Tube Carcinomas in the United States, 1995-2004 , 2009, Cancer Epidemiology Biomarkers & Prevention.
[10] L. Dubeau,et al. The cell of origin of ovarian epithelial tumours. , 2008, The Lancet. Oncology.
[11] J. Seidman,et al. Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma. , 2007, Gynecologic oncology.
[12] A. Borczuk,et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin? , 2007, Modern Pathology.
[13] M. Barchana,et al. Malignancies following bilateral salpingo-oophorectomy (BSO). , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[14] S. Narod,et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. , 2005, Gynecologic oncology.
[15] Susan L Neuhausen,et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.
[16] L. Leider-Trejo,et al. Primary papillary serous carcinoma of the peritoneum in a man. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] T. Stanley,et al. Papillary serous carcinoma of the peritoneum in a man , 1998, Cancer.
[18] E. Sivan,et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. , 1996, Gynecologic oncology.
[19] R. Berkowitz,et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. , 1995, Cancer research.
[20] L. Dubeau,et al. Ovarian tumor development: insights from ovarian embryogenesis. , 2001, European journal of gynaecological oncology.